1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Roche Sees Glass Half Full After Ipatasertib Data

Hit One Co-Primary Endpoint, Missed The Other

 
• By Kevin Grogan

Roche’s ipatasertib has improved progression-free survival in a sub-group of previously untreated metastatic castration-resistant prostate cancer patients – those whose tumors had PTEN loss – in a Phase III study. However the AKT inhibitor failed to cut the risk of disease worsening or death in the broader population.

Glass_Of_Water
Roche accentuates the positive in ipatasertib study • Source: Shutterstock

Roche's hopes of breaking into the prostate cancer market have been slightly knocked following mixed results from a late-stage trial of ipatasertib, the Swiss major's investigational AKT inhibitor.

The Phase III IPATential150 study is evaluating ipatasertib in combination with Johnson & Johnson's blockbuster Zytiga (abiraterone) and prednisone/prednisolone...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

More from Therapy Areas

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 
• By Jessica Merrill

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Novo Nordisk Teams With Deep Apple On Non-Incretin Obesity Approach

 
• By Joseph Haas

Novo Nordisk will partner with privately held Deep Apple to study a novel, non-incretin target that could be better suited than GLP-1s for long-term obesity treatment.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.